Cited by 133Treatment of Major DepressionElectroconvulsive Therapy StudiesNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression

Open access

Lener, Marc S., Kadriu, Bashkim, Zarate, Carlos A.·2017·Drugs

DOI 10.1007/s40265-017-0702-8PMC PMC5342919

Open this paper in CoChat — free account Open PDF

Abstract

Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individuals with major depressive disorder and bipolar depression, rapid reductions in depressive symptoms have been observed in response to subanesthetic-dose ketamine, an agent whose mechanism of action involves the modulation of glutamatergic signaling. The findings from these studies have prompted the repurposing and/or development of other glutamatergic modulators for antidepressant efficacy, both as monotherapy or as an adjunct to conventional monoaminergic antidepressants. This review highlights the evidence supporting the antidepressant effects of subanesthetic-dose ketamine as well as other glutamatergic modulators, such as D-cycloserine, riluzole, CP-101,606, CERC-301 (previously known as MK-0657), basimglurant, JNJ-40411813, dextromethorphan, nitrous oxide, GLYX-13, and esketamine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s40265-017-0702-8

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
Retracted
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citation
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Stress signalling pathways that impair prefrontal cortex structure and function
Arnsten, A. F. T. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2648 · Cited by 3,299
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citation

Show all 131 references

Sorted by citations

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070720 · Cited by 802
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.20101429 · Cited by 795
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citation
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Major depressive disorder: Validated treatments and future challenges
Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i31.9350 · Cited by 232
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
Ketamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis
Kim, R., Healey, K. L., Sepulveda-Orengo, M. T., & Reissner, K. J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.002 · Cited by 154
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Psychedelic drugs—a new era in psychiatry?
Nutt, D. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.2/dnutt · Cited by 147
A brief history of antidepressant drug development: from tricyclics to beyond ketamine
Pereira, V. S., & Sato, V. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.39 · Cited by 135
The Nucleus Accumbens: A Common Target in the Comorbidity of Depression and Addiction
Xu, L., Nan, J., & Lan, Y. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.00037 · Cited by 123
Ketamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
The anterior cingulate cortex as a key locus of ketamine’s antidepressant action
Alexander, L., Jelen, L. A., Mehta, M. A., & Young, A. H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.003 · Cited by 83
The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Kalmoe, M. C., Janski, A. M., Zorumski, C. F., Nägele, P., Palanca, B. J. A., & Conway, C. R. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116778 · Cited by 78
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 78
Self-citation
A Review of Nonanesthetic Uses of Ketamine
Pribish, A. M., Wood, N. J., & Kalava, A. (2020) · Anesthesiology Research and Practice · doi:10.1155/2020/5798285 · Cited by 73
Ketamine for Bipolar Depression: A Systematic Review
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 70
Self-citation
Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool
Lazarevic, V., Yang, Y., Ivanova, D., Fejtová, A., & Svenningsson, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.021 · Cited by 61
On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods
Strong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 63
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
Sex differences in resilience: Experiential factors and their mechanisms
Fallon, I. P., Tanner, M. K., Greenwood, B. N., & Baratta, M. V. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14639 · Cited by 62
Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression
Vidal, S. I., Gex‐Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A. G., Virginie Sterpenich, A., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 51
Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Esketamine has nearly fourfold greater afﬁnity for the NMDAR than (R)-ketamine but interestingly induces fewer and weaker psychotomimetic and dissociative effects [103].”
BackgroundResultInfluential
Behavioral and neuropsychiatric disorders in Alzheimer's disease
Cortés, N., Andrade, V., & Maccioni, R. B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180005 · Cited by 57
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 46
A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats
Rodríguez, P. M., Urbanavicius, J., Prieto, J. P., Fabius, S., Reyes, A. L., Havel, V., Sameš, D., Scorza, C., & Carrera, I. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00152 · Cited by 44
Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders
Nedelcovych, M. T., Kim, B.-H., Zhu, X., Lovell, L. E., Manning, A. A., Kelschenbach, J., Hadas, E., Chao, W., Prchalová, E., Dash, R. P., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09859-w · Cited by 41
Withdrawal from chronic ethanol exposure increases postsynaptic glutamate function of insular cortex projections to the rat basolateral amygdala
McGinnis, M. M., Parrish, B. C., & McCool, B. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108129 · Cited by 38
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male mice
Crowley, N. A., Magee, S. N., Feng, M., Jefferson, S. J., Morris, C., Dao, N. C., Brockway, D. F., & Lüscher, B. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.003 · Cited by 34
Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity
Śniecikowska, J., Głuch‐Lutwin, M., Bucki, A., Więckowska, A., Siwek, A., Jastrzębska‐Więsek, M., Partyka, A., Wilczyńska, D., Pytka, K., Pociecha, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00062 · Cited by 36
Drug repurposing may generate novel approaches to treating depression
Ebada, M. E. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12815 · Cited by 36
Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model
Depoortère, R., Papp, M., Gruca, P., Łasoń, M., Niemczyk, M., Varney, M. A., & Newman‐Tancredi, A. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119860666 · Cited by 35
Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression (SAINT-TRD)
Cole, E., Gulser, M., Stimpson, K., Bentzley, B., Hawkins, J., Xiao, X., Schatzberg, A., Sudheimer, K., & Williams, N. (2019) · Brain Stimulation · doi:10.1016/j.brs.2018.12.299 · Cited by 31
Modulation of DNA Methylation and Gene Expression in Rodent Cortical Neuroplasticity Pathways Exerts Rapid Antidepressant-Like Effects
Sales, A. J., Maciel, I. D. S., Suavinha, A. C. D. R., & Joca, S. R. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02145-4 · Cited by 28
Remembering Mechanosensitivity of NMDA Receptors
Johnson, L. R., Battle, A. R., & Martinac, B. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00533 · Cited by 27
New agents and perspectives in the pharmacological treatment of major depressive disorder
Sanches, M., Quevedo, J., & Soares, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110157 · Cited by 26
Proteomics Study Reveals the Anti-Depressive Mechanisms and the Compatibility Advantage of Chaihu-Shugan-San in a Rat Model of Chronic Unpredictable Mild Stress
Zhu, X., Li, T., Hu, E., Duan, L., Zhang, C., Wang, Y., Tang, T., Yang, Z., & Fan, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.791097 · Cited by 25
Intravenous infusion of xenon-containing liposomes generates rapid antidepressant-like effects
Dandekar, M. P., Peng, T., McPherson, D. D., Quevedo, J., Soares, J. C., & Huang, S. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.011 · Cited by 25
Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies
Crisanti, C., Enrico, P., Fiorentini, A., Delvecchio, G., & Brambilla, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.119 · Cited by 23
The human neurosecretome: extracellular vesicles and particles (EVPs) of the brain for intercellular communication, therapy, and liquid-biopsy applications
Soleymani, T., Chen, T.-Y., Gonzalez‐Kozlova, E., & Dogra, N. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1156821 · Cited by 22
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment
Srikumar, B. N., Paschapur, M. S., Kalidindi, N., Adepu, B., Das, M. L., Sreedhara, M. V., Kuchibhotla, V. K., Pieschl, R. L., Li, Y.-W., Ega, D. S. P., et al. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.003 · Cited by 21
mGluR5 Facilitates Long-Term Synaptic Depression in a Stress-Induced Depressive Mouse Model
Jiang, X., Lin, W., Cheng, Y., & Wang, D. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719874162 · Cited by 18
Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK)
Herzog, D. P., Perumal, N., Manicam, C., Treccani, G., Nadig, J., Rossmanith, M., Engelmann, J., Jene, T., Hasch, A., van der Kooij, M. A., et al. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100404 · Cited by 19
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham, A., Avila-Quintero, V. J., Bloch, M. H., & Dwyer, J. B. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0086 · Cited by 20
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gutiérrez, G., Swainson, J., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116125 · Cited by 19
Intensive rTMS for treatment-resistant depression patients with suicidal ideation: An open-label study.
Wang, Q., Huang, H., Li, D., Wang, Y.-T., Qi, N., Ci, Y., & Xu, T.-C. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103189 · Cited by 20
Ketamine: Recent evidence and current uses
Afify, E. E. S., Mohamed, S., & Khedr, M. B. (2023) · Benha Journal of Applied Sciences · doi:10.21608/bjas.2023.208756.1165 · Cited by 18
Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder
Bristow, L. J., Gulia, J., Weed, M. R., Srikumar, B. N., Li, Y.-W., Graef, J. D., Naidu, P. S., Sanmathi, C., Aher, J., Bastia, T., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242784 · Cited by 18
BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder
Marcin, L. R., Warrier, J., Thangathirupathy, S., Shi, J., Karageorge, G. N., Pearce, B. C., Ng, A., Park, H., Kempson, J., Li, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00080 · Cited by 18
Polyfluorinated scaffolds in drug discovery
Pertusati, F., Serpi, M., & Pileggi, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812733-9.00003-9 · Cited by 17
New medications for treatment-resistant depression: a brief review of recent developments
Thase, M. E. (2017) · CNS Spectrums · doi:10.1017/s1092852917000876 · Cited by 15
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials
Yao, R., Wang, H., Yuan, M., Wang, G., & Wu, C. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112750 · Cited by 14
Key considerations in the pharmacological management of treatment-resistant depression
Yavi, M., Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1951225 · Cited by 14
Self-citation
(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity
Riggs, L. M., Thompson, S. M., & Gould, T. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109153 · Cited by 15
Positive effects of running exercise on astrocytes in the medial prefrontal cortex in an animal model of depression
Huang, D., Xiao, Q., Tang, J., Liang, X., Wang, J., Hu, M., Jiang, Y., Liu, L., Qin, L., Zhou, M., et al. (2022) · The Journal of Comparative Neurology · doi:10.1002/cne.25397 · Cited by 13
Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 13
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models
Papp, M., Gruca, P., Łasoń, M., Litwa, E., Newman‐Tancredi, A., & Depoortère, R. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06389-5 · Cited by 16
1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators
Chrovian, C. C., Soyode-Johnson, A., Wall, J. L., Rech, J. C., Schoellerman, J., Lord, B., Coe, K. J., Carruthers, N. I., Nguyen, L., Jiang, X., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00542 · Cited by 13
Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico–Striatal Loop That Are Implicated in Major Depression
Ferber, S. G., Weller, A., Yadid, G., & Friedman, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041867 · Cited by 14
Bringing Neuroscience to the Bedside
Cooper, J. J., Korb, A. S., & Akil, M. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180033 · Cited by 13
The N -methyl- d -aspartate receptor hypothesis of ketamine’s antidepressant action: evidence and controversies
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 11
NMDA and AMPA receptor physiology and role in visceral hypersensitivity: a review
Cheng, F., Du, L., Kim, J. J., Zhu, F., He, H., & Dai, N. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002351 · Cited by 10
Exploring real-world evidence to uncover unknown drug benefits and support the discovery of new treatment targets for depressive and bipolar disorders
Teneralli, R. E., Kern, D. M., Cepeda, M. S., Gilbert, J. P., & Drevets, W. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.096 · Cited by 10
Plasma kynurenine pathway metabolite levels increase in depressed patients after antidepressant treatment
Colle, R., Chappell, K., Asmar, K. E., Fève, B., Chanson, P., David, D. J. P., Verstuyft, C., Becquemont, L., & Corruble, E. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.05.025 · Cited by 10
The Regulation of Glutamate Transporter 1 in the Rapid Antidepressant-Like Effect of Ketamine in Mice
Chen, Y., Shen, M., Liu, X., Xu, J., & Wang, C. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.789524 · Cited by 9
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee
Gutiérrez, G., Vázquez, G. H., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251347360 · Cited by 8
The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine
Trenado, C., Seifritz, E., Olbrich, S., & Ferrea, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120751 · Cited by 8
NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models
Jordan, W., Siegel, R., Kumar, R., & Javitt, J. C. (2023) · International Journal of Toxicology · doi:10.1177/10915818231176971 · Cited by 8
Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation
Chen, M., Lin, W., Li, C., Wu, H.-J., Bai, Y., Tsai, S., Su, T., & Tu, P. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.07.022 · Cited by 8
Quantitative behavioural phenotyping to investigate anaesthesia induced neurobehavioural impairment
Nambyiah, P., & Brown, A. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-98405-x · Cited by 7
Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review
Barbosa, M. G., Garcia, G. T., Sarin, L. M., & Jackowski, A. P. (2022) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2876 · Cited by 9
Discovery of novel tryptamine derivatives as GluN2B subunit-containing NMDA receptor antagonists via pharmacophore-merging strategy with orally available therapeutic effect of cerebral ischemia
Quan, J., Yang, H., Qin, F., He, Y., Liu, J., Zhao, Y., Ma, C., & Cheng, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115318 · Cited by 8
Impact of ketamine administration on chronic unpredictable stress‐induced rat model of depression during extremely low‐frequency electromagnetic field exposure: Behavioral, histological and molecular study
Salari, M., Eftekhar‐Vaghefi, S. H., Asadi‐Shekaari, M., Esmaeilpour, K., Solhjou, S., Amiri, M., & Ahmadi‐Zeidabadi, M. (2023) · Brain and Behavior · doi:10.1002/brb3.2986 · Cited by 7
Glutamate-Glutamine Transfer and Chronic Stress-Induced Sex Differences in Cocaine Responses
Shimamoto, A., Rappeneau, V., Munjal, H., Farris, T., Davis, C. R., Wilson, A., Edwards, M., Moore, C., Reynolds, C., & Meshul, C. K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.009 · Cited by 8
Adjunct ketamine treatment of depression in treatment‐resistant schizophrenia patients is unsatisfactory in pilot and secondary follow‐up studies
Zhuo, C., Lin, X., Tian, H., Liu, S., Bian, H., & Chen, C. (2020) · Brain and Behavior · doi:10.1002/brb3.1600 · Cited by 8
Effects of GRIN2B, GRIA1, and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial
Beanes, G., Caliman‐Fontes, A. T., Souza‐Marques, B., Silva, H. D. S., Leal, G. C.-G., Carneiro, B. A., Guerreiro‐Costa, L. N. F., Figueiredo, A. V., Figueiredo, C. A., Lacerda, A. L. T., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000517 · Cited by 7
Anesthesia for patients with psychiatric illnesses: a narrative review with emphasis on preoperative assessment and postoperative recovery and pain
Stamenković, D., Selvaraj, S., Venkatraman, S., Arshad, A., Rančić, N., Dragojevic-Simic, V. M., Miljković, M. N., & Cattano, D. (2020) · Minerva Anestesiologica · doi:10.23736/s0375-9393.20.14259-7 · Cited by 8
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression
Fava, V. A. R., Sarin, L. M., Lucchese, A. C., Sant, L. C. D., Magalhães, E. T. P., Delfino, R. S., Tuena, M. A., Nakahira, C., Jackowski, A. P., Abdo, G. L., et al. (2020) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2020.10.003 · Cited by 6
Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
Gutiérrez, G., Rosenblat, J. D., Hawken, E. R., Swainson, J., & Vázquez, G. H. (2022) · JMIR Research Protocols · doi:10.2196/34711 · Cited by 7
Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
Vázquez, G. H., Gutiérrez, G., Rosenblat, J. D., Schaffer, A., Swainson, J., Ganapathy, K., Ravindran, N., Lam, R. W. M., Do, A., Giacobbe, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060967 · Cited by 8
Functional connectivity changes with rapid remission from moderate-to-severe major depressive disorderPreprint
Xiao, X., Bentzley, B. S., Cole, E. J., Tischler, C., Stimpson, K. H., Duvio, D., Bishop, J. H., DeSouza, D. D., Schatzberg, A. F., Keller, C. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/672154 · Cited by 7
Simultaneous Application of Lidocaine and Ketamine During Ambulatory Infusion Therapy: A Retrospective Analysis
Striebel, J., Ruppen, W., & Schneider, T. (2023) · Pain Management · doi:10.2217/pmt-2023-0037 · Cited by 8
Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial
Penaluna, B. K., Voort, J. L. V., Bobo, W. V., Pazdernik, V., Achtyes, E. D., Goes, F. S., Greden, J. F., Parikh, S. V., Frye, M. A., & Singh, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119414 · Cited by 5
Esketamine for postoperative analgesia after cesarean section: Effects on pain, mood, sleep quality, and safety
Zhang, B., & Zhou, Q. (2025) · Medicine · doi:10.1097/md.0000000000044432 · Cited by 5
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial
Maji, S., Mishra, A., Mohapatra, D., Mishra, B. R., Jena, M., Srinivasan, A., & Maiti, R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116257 · Cited by 5
Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia?
Chiu, S., Farina, M. W., Terpstra, K. J., Badmaev, V., Cernovsky, Z. Z., Bureau, Y., Jirui, J., Raheb, H., Husn, M., Copen, J., et al. (2017) · Journal of Clinical Epigenetics · doi:10.21767/2472-1158.100066 · Cited by 5
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
Irwin, M. N., & VandenBerg, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.05.200 · Cited by 7
Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol
Maji, S., Mohapatra, D., Jena, M., Srinivasan, A., & Maiti, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080500 · Cited by 4
Inhibition of SERT and NMDAR synergistically confers rapid antidepressant effects of ketamine
Luo, H., Chen, M., Ning, Y., Ren, L., Lu, Y., Sun, J., Zhu, X., Ran, M., Guo, J., Lu, C., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf367 · Cited by 4
Next generation antidepressants with novel mechanisms for treatment resistant depression
Chen, M., Tu, P., & Su, T. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.005 · Cited by 3
Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine
Hashmi, M., Mugunthan, P., Jain, P., Nimmakayala, T., & Alnaher, S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1527166 · Cited by 3
Effect of ketamine infusion in treatment resistant depression and in depressive patients with active suicidal ideations: a study from North India
Rasool, U., Jan, N., Zahoor, M., Roub, F., Rather, Y. H., Hussain, A., & Najeeb, R. (2023) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20230029 · Cited by 2
Association of the GRIK4 rs1954787 polymorphism with clinical response in antidepressant-treated depressed patients: results from a prospective cohort and meta-analysis
Chappell, K., Colle, R., Asmar, K. E., Gressier, F., Bouligand, J., Trabado, S., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02765-5 · Cited by 2
Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections
Barbosa, M. G., Sarin, L. M., Tuena, M. A., Sant, L. C. D., Nakahira, C., Magalhães, E. T. P., Fava, V. A. R., Delfino, R. S., Steglich, M. S., Puertas, C. B., et al. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100053 · Cited by 2
Brain Glutamate Dynamics Predict Positive Agency in Healthy Women: Insights from Combined Application of Pharmacological Challenge, Comprehensive Affective Assessment, and Magnetic Resonance Spectroscopy
White, T. L., Gonsalves, M. A., Harris, A. D., Walsh, E. G., & Joyce, H. E. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00521 · Cited by 2

Authors: Lener, M. S., Kadriu, B., & Zarate, C. A.
Affiliations: National Institutes of Health (US)
Corresponding author: Lener, Marc S.
ORCID: Kadriu, Bashkim
Zarate, Carlos A.
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 2017-02-14
Volume: 77
Issue: 4
Pages: 381-401
ISSN: 0012-6667 (ISSN-L)
1179-1950
DOI: 10.1007/s40265-017-0702-8
PMC: PMC5342919
OpenAlex: W2588408561
Cited by: 131
References: 131
Citations by year: 2026: 2 · 2025: 10 · 2024: 11 · 2023: 16 · 2022: 18 · 2021: 17 · 2020: 19 · 2019: 14 · 2018: 15 · 2017: 9
FWCI: 2.01
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, public-domain)
Funders: National Institute of Mental Health (ZIA-MH002857-10)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: ketamine, depression, major depressive disorder, bipolar depression, antidepressant repurposing, subanesthetic ketamine, D-cycloserine, riluzole, CP-101,606, dextromethorphan, nitrous oxide, esketamine, glutamatergic signaling
MeSH terms: Depression, Humans, Ketamine, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks